By Heather Landi
Teladoc CEO Jason Gorevic is bullish that Teladoc can win in the market in the long run despite current market volatility and growing competition from well-funded startups. As virtual care evolves and becomes more integrated into healthcare, Teladoc has the scale, capabilities and depth of expertise to lead the sector, he told Fierce Healthcare in a recent interview.
read more
By Zoey Becker
After the FDA's independent vaccine committee voted to update COVID-19 shots, the agency recommends that manufactures update their vaccines to target omicron subvariants BA.4 and BA.5.
read more
By Andrea Park
Too many cooks in the kitchen may spoil the broth, but medtech developers are betting that adding increasingly more tech tools to the operating room will only improve procedure success rates.
read more
By Gabrielle Masson
Heron Therapeutics has joined the gaggle of biotechs laying off staff, cutting a third of its workforce as part of restructuring efforts that could bring an annual $43 million in savings.
read more
By Eric Sagonowsky
Increasingly, cell and gene therapies are changing the treatment landscape for cancers and rare diseases. But how will the system pay for them?
read more
By Robert King
HHS reached a $3.2 billion deal with Pfizer to purchase 105 million doses of the drug manufacturer's COVID-19 vaccine in anticipation of a fall campaign.
read more
By Andrea Park
“I am disappointed to have to step back from my role as president and CEO of Hyperfine. It has been an honor to lead the company through our first full year of commercialization and our transition to becoming a publicly listed company,” said Dave Scott, citing personal reasons.
read more
By Max Bayer
After raising more than $660 million in less than a year, Eikon Therapeutics' future plans are coming into clearer view, with an oncology pipeline underway as the star-studded biotech looks to capitalize on—and expand—Nobel Prize-winning tech.
read more
By Paige Minemyer
Banner Health has signed on with Hue Health and Flume Health to launch a new health plan built around direct primary care.
read more
By Gabrielle Masson
WindTree Therapeutics has the clinical results it wants—but is missing the bull market, meaning the biotech is exploring strategic options amid the market downturn.
read more
By Angus Liu
Novartis has put an end to a radiotherapy production hiccup, and expansions are already underway. The Swiss pharma is investing to expand the very two manufacturing facilities that caused the latest supply freeze for the U.S.
read more
By Conor Hale
To gain a clearer picture when screening people for the early signs of lung cancer, Philips is looking to bolster its CT scanning approach with blood-based tests developed by Biodesix.
read more
